Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer - Wikidata - awgldk - TriplyDB

Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer

Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer

http://www.wikidata.org/entity/Q24630174

about

Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment Molecular therapeutics in pancreas cancer Genomic alterations in pancreatic cancer and their relevance to therapy Novel agents for advanced pancreatic cancer One mouse, one patient paradigm: New avatars of personalized cancer therapy Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated Proteins Targeting the RAS oncogene.Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment.Kras as a key oncogene and therapeutic target in pancreatic cancer Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.Interplay Between HGF/SF-Met-Ras Signaling, Tumor Metabolism and Blood Flow as a Potential Target for Breast Cancer Therapy Drugging the undruggable RAS: Mission possible?Small-molecule modulation of Ras signaling.Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives.Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib.How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.Therapeutic Approaches to RAS Mutation.A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice Carcinogenesis of pancreatic adenocarcinoma: precursor lesions.Metabolism addiction in pancreatic cancer.Nanomicellar carriers for targeted delivery of anticancer agents.Enhancing FTS (Salirasib) efficiency via combinatorial treatment.Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?Current status of the development of Ras inhibitors.Galectin-1 dimers can scaffold Raf-effectors to increase H-ras nanoclustering.Synthesis and biological evaluation of hybrids from farnesylthiosalicylic acid and hydroxylcinnamic acid with dual inhibitory activities of Ras-related signaling and phosphorylated NF-κB.Synthesis and biological evaluation of novel farnesylthiosalicylic acid derivatives for cancer treatment.Emerging protein kinase inhibitors for treating pancreatic cancer.Ras nanoclusters: a new drug target?Combined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics.Cancer: Drug for an 'undruggable' protein.Improving Therapeutic Potential of Farnesylthiosalicylic Acid: Tumor Specific Delivery via Conjugation with Heptamethine Cyanine Dye.Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells.Targeted Therapies for Pancreatic Cancer.Is Ras a potential target in treatment against cutaneous squamous cell carcinoma?

P2860

Q26740619-EAC7B7A1-A5E8-41A3-B5B8-1D0191EEBE44 Q26751709-4B3E9AB8-C037-440E-BDAD-49B1C48F8628 Q26781443-C019C160-3F6C-4858-A297-76F83698E9E1 Q26787087-4D0DCFF3-B02A-4214-9513-BAED509CE843 Q27023342-642FDDFD-2510-4DCD-AB6B-F6F93F00F55F Q27027458-CA8F03E5-AADE-47B5-8649-77D3734E54A2 Q27687198-2DC9FBAB-5330-4C41-B5FF-96864AE7A38E Q28066268-1555A958-7714-4C34-988A-AB048A064D0D Q33838679-F98B3904-D2AD-4181-9280-1D9FC82507DD Q34659332-C7A9ECC1-9150-4F6F-BE09-633F5BD4292E Q34659415-FD6AF40D-3625-4788-8A82-5B5F30C50101 Q34971882-24D2489A-9D0B-402B-A2F9-322FA2C66D07 Q35163434-6CC7809A-6A78-4F04-B05C-9D9646E88F36 Q35188280-FF1B6605-5165-4704-B334-CE0D2FA9E6B0 Q35872060-5FBBFDF4-6B84-408F-99D2-40BD1ADFD6A1 Q36275798-9CD1A6DB-62C3-4D1D-8391-EAA5A105878B Q37016586-572166A4-2C7B-4250-98B0-ED73864D8D49 Q37113976-D39EB401-1CD1-472C-9BE1-EFE3CA398099 Q37122874-C12B684B-0466-4B4F-9E1A-F52EFEEA9830 Q37285560-6D551054-50D1-4E7F-9BDD-EB8D3FDB2917 Q37291172-7DFB9DBE-ADAA-47DC-8C67-B5D93C5DA9C2 Q37620679-C09F5681-264E-4521-BB40-3B104821BE5F Q38171564-133A06F9-966C-4B9A-BBA7-373A1E584B21 Q38367291-3A42A67C-A103-469B-914F-2911A04FF057 Q38423044-1780F021-30B5-4221-B912-32098983FBC9 Q38534932-E23D7184-1E1B-405E-961B-5F0DA4AE5C06 Q38777463-6240B490-2340-4433-AD1F-CF36957A8BD9 Q38992986-10FD830A-00AE-432D-8F85-FD4CE15235AA Q39033581-A2B0D1C8-862A-4732-9293-EB5655D4EF84 Q39158411-C6206FA5-0E39-42D2-A992-C3A49DF59252 Q39465453-2FD023CB-8EC2-46D2-9175-F147D08EF82F Q41497028-487A4DE6-13E2-4022-9160-C8C7B858FDBD Q42734596-C96F5FD2-ACEA-43F0-B960-227912ED14A6 Q46685190-407E517B-55A5-430D-AAD2-C919B40C6AA8 Q47155582-F47CD43E-018D-4FEA-AA76-3418A0AB307B Q55015991-C311A900-BF26-4488-91DE-6645D6116117 Q57116365-1A159D64-E5DA-4D16-9E98-D372DE28AC5A

P2860

Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer

http://www.wikidata.org/entity/Q24630174

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Integrated preclinical and cli ...... alirasib) in pancreatic cancer

@ast

Integrated preclinical and cli ...... alirasib) in pancreatic cancer

@en

Integrated preclinical and cli ...... alirasib) in pancreatic cancer

@nl

type

label

Integrated preclinical and cli ...... alirasib) in pancreatic cancer

@ast

Integrated preclinical and cli ...... alirasib) in pancreatic cancer

@en

Integrated preclinical and cli ...... alirasib) in pancreatic cancer

@nl

prefLabel

Integrated preclinical and cli ...... alirasib) in pancreatic cancer

@ast

Integrated preclinical and cli ...... alirasib) in pancreatic cancer

@en

Integrated preclinical and cli ...... alirasib) in pancreatic cancer

@nl

P1433

Q24630174-83644157-69FF-4A72-9D88-384DD169C835

P1476

Q24630174-19F2217F-D837-4088-8720-A08AB7C02694

P2093

Q24630174-0673B207-FCA6-4BFF-88D1-1C36119562F8

Q24630174-3AC52E3B-5883-434A-B76A-AF4A86BAF503

Q24630174-52FF3C2D-0868-4398-B4B3-81FBECCE9914

Q24630174-649DBC6F-EFF1-45EE-B018-20CBA862C3E2

Q24630174-67209DB0-9E29-407D-84AD-CA181E630E15

Q24630174-6B2EE125-41FD-44A9-9632-817F876A19DD

Q24630174-8001A68A-384B-4B1D-AEB8-20F716354571

Q24630174-A19D08D7-BEA3-47E8-B29C-ED4DCB853C3B

Q24630174-AFFA2863-90CE-4147-8D41-DEEC5ECE5DEF

Q24630174-C02CF158-226E-4E81-AB5D-28A17FD95043

P2860

Q24630174-06C1D635-87B0-4D67-8BAB-C92480511A18

Q24630174-0BD592C0-AC22-45D3-87B6-FBE5067EB92E

Q24630174-2749689F-BDC6-497C-8C1C-7E23F2B7561D

Q24630174-3DAA3770-8B3F-41A8-9078-9F7CFEDA7D41

Q24630174-40ED4A18-AB45-4B34-AC52-85E92A63E190

Q24630174-4642DA04-6A66-4074-BA34-F3CB9D310FA2

Q24630174-4E9844E6-08AA-4B37-A98B-C97FED6C48CF

Q24630174-65C79303-A9AF-43CA-A11B-BE4E8378CE0A

Q24630174-7C105DDB-6293-49D6-8BFB-AC30B531BD7C

Q24630174-81ABEAB5-A943-4B38-9BFE-969E7D7983B1

P2888

Q24630174-DAAF2BB8-96C7-4DD9-A622-DDC62FA59BDC

P304

Q24630174-5A6B1208-CB33-4C6C-9F7E-E0825530B038

P31

Q24630174-713617F7-3381-479C-AE6A-D02A5520B663

P3181

Q24630174-6CC74B47-108D-4721-A045-F79FC9AD8993

P356

Q24630174-CAB3930F-1FBA-4A1A-8FAC-666022F279E2

P407

Q24630174-6F1A143A-E222-4ED4-9408-194BD1C3A25D

P433

Q24630174-9B9DC31A-3EB3-40EC-AAD6-FE279D92181A

P478

Q24630174-23ED27A4-D4C7-4308-BCDB-8A59E9221CD4

P50

Q24630174-A3EFA083-B780-43E4-AE05-C8B6389FB2E8

P577

Q24630174-51F2C801-6BA6-4297-9941-9C4E74A74278

P6179

Q24630174-4F079E1F-DA9B-4DAE-A224-0380309BE435

P698

Q24630174-DE54A30C-CBD0-4194-86FD-D3D1BEE3E063

P932

Q24630174-259B4439-3B01-4E24-BABD-C9538D60EF37

P3181

P356

S10637-012-9818-6

P1433

Investigational New Drugs

P1476

Integrated preclinical and cli ...... alirasib) in pancreatic cancer

@en

P2093

Antonio Jimeno

http://www.w3.org/2001/XMLSchema#string

Daniel Laheru

http://www.w3.org/2001/XMLSchema#string

Dongweon Song

http://www.w3.org/2001/XMLSchema#string

Dung T Le

http://www.w3.org/2001/XMLSchema#string

Florencia McAllister

http://www.w3.org/2001/XMLSchema#string

Gretchen Taylor

http://www.w3.org/2001/XMLSchema#string

Howard Goldsweig

http://www.w3.org/2001/XMLSchema#string

Michelle A Rudek

http://www.w3.org/2001/XMLSchema#string

Ming Zhao

http://www.w3.org/2001/XMLSchema#string

N V Rajeshkumar

http://www.w3.org/2001/XMLSchema#string

P2860

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Pancreatic cancer

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.

P2888

s10637-012-9818-6

P304

2391-2399

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2262363

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S10637-012-9818-6

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1013809176

http://www.w3.org/2001/XMLSchema#string

P698

22547163

http://www.w3.org/2001/XMLSchema#string

P932

3557459

http://www.w3.org/2001/XMLSchema#string